Ignite Creation Date:
2024-05-05 @ 11:52 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00154726
Status:
COMPLETED
Last Update Posted:
2005-11-22
First Post:
2005-09-08
Brief Title:
Paclitaxel-HDFL for Locally Advanced and RecurrentMetastatic Gastric Cancers
Sponsor:
National Taiwan University Hospital
Organization:
National Taiwan University Hospital
Study Overview
Official Title:
A Phase II Study of Weekly PaclitaxelTaxoland 24-Hour Infusion High-Dose 5-Fluorouracil and LeucovorinHDFLin the Treatment Locally Advanced and RecurrentMetastatic Gastric Cancers
Status:
COMPLETED
Status Verified Date:
2005-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacyresponse ratetime to treatment failureoverall survivaltoxicities of Paclitaxel-HDFL regimen in locally advancedinoperable and recurrentmetastatic gastric cancers To evaluate the resectability and relapse pattern after potentially curative resection of neoadjuvant Paclitaxel-HDFL regimen
Detailed Description:
In the treatment of metastatic breast cancer paclitaxel followed by weekly HDFL has been shown to have a 55 response rate in anthracycline-resistant patient Recently regimen combining paclitaxel and moderately-high-dose 5-FU 1500mgm2 has had response rate up to 615 including 23CR in a small group of gastric cancer patients 8 responders in 13 patients Thus the sequential use of weekly paclitaxel followed by weekly HDFL regimen may become a new generation of chemotherapeutic regimen for the treatment of gastric cancer Further study with a larger group of patients and further testing of possible schedules of administration are warranted
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None